BSE: 500674
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -12.76% and Sensex by -24.24%
MARKET CAP (Mid Cap Stock)Rs 13,196 Cr
PE (TTM) 24.19
PE Ratio24.67
Price to Book Value9.06
EV to EBIT18.87
EV to EBITDA17.75
EV to Capital Employed16.06
EV to Sales4.51
PEG Ratio0.00
Dividend Yield11.94%
ROCE (Latest)81.59%
ROE (Latest)36.72%
NameDec 22Sep 22
Promoters (Change:0.00) 60.4%60.4%
FIIs (Change:-1.27) 6.99%8.26%
Mutual Funds (Change:-0.05) 9.4%9.45%
Insurance Companies (Change:1.00) 9.82%8.82%
Other DIIs (Change:-0.01) -0%0.01%
Non Institution (Change:0.33) 13.4%13.07%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in Sanofi India

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of Sanofi India Ltd (SANOFI)?

Sanofi India Ltd (SANOFI) share price as of April 1, 2023, on NSE is Rs 5,735.40 (NSE) and Rs 5,739.90 (BSE) on BSE.

Can I buy Sanofi India Ltd (SANOFI) shares?

Yes, You can buy Sanofi India Ltd (SANOFI) shares by opening a Demat account with Angel One.

How do I buy Sanofi India Ltd (SANOFI) from Angel One?

Sanofi India Ltd (SANOFI) share can be brought through the following modes:
  1. Direct investment: You can buy Sanofi India Ltd (SANOFI) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sanofi India Ltd (SANOFI) shares.

In which sector do Sanofi India Ltd (SANOFI) belong?

Sanofi India Ltd (SANOFI) belongs to Pharma.


Today's live share price for Sanofi India is NSE: ₹ 5,735.40, BSE: ₹ 5,739.90 with a current market capitalization of .

Aventis Pharma Ltd is a pharmaceutical company that discovers, develops and markets branded prescription drugs and vaccines to protect and improve the quality of life of people around the world. The company provides medicines for the treatment of patients in several therapeutic areas such as Cardiovascular Disease, Thrombotic Diseases, Metabolic Disorders, Oncology, Disorders of the Central Nervous System, Internal medicine and Vaccines. They are having their manufacturing facilities at Ankleshwar in Gujarat and Verna in Goa. The company also manufactures their products on loan license which are manufactured in accordance with the same quality standards as those prevalent at their manufacturing sites. Aventis Pharma Ltd was incorporated in May 1956 under the name Hoechst Fedco Pharma Pvt Ltd. Over the years, the name was changed to Hoechst Pharmaceuticals Pvt Ltd, Hoechst India Ltd and Hoechst Marion Roussel Ltd. Sanofi-aventis, one of the world's leading pharmaceutical companies, and their 100% subsidiary, Hoechst GmbH, are the major shareholders of Aventis Pharma Ltd and together hold 50.12% of their paid-up share capital. During the year 1997-98, the joint venture company Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine 'Rabipur'. Roussel India Ltd was amalgameted with the company with effect from April 1 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary company in Nepal has been wound up during the year. During the year 1999-2000, Aventis has launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H. In the year 2001, Rhone-Poulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the world's first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched. In the year 2004, the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the company's paid-up share capital. In the year 2006, the company completed the project for setting up additional facilities for manufacturing Combiflam Tablets in Ankleshwar, Gujarat. In the year 2007, the company launched Cardace H 10 mg as a comprehensive cardiovascular treatment option in hypertension at risk patients. In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam tablets was installed in Ankleshwar. This product which was being manufactured partly in a toll manufacturing site is now planned to be manufactured entirely in Ankleshwar. The company brands namely Combiflam, Cardace, Rabipur, Amaryl, Avil and AllegraTM feature in the top 100 brands of the retail market. In that, Cardace continues to be the number one cardiovascular brand in the Indian pharmaceutical market. The company plans to upgrade the capacities in Ankleshwar for the manufacture of Combiflam. Also, the Ankleshwar API plant will commence manufacture of Pentoxifylline which was so far imported and is the raw material for manufacture of Trental. The product will also be exported to Hungary. In April 2008, the company has launched a new prefilled diaposable insulin pen, SoloStar for use with the 24-hour insulin Lantus. This disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers